

ESMO Preceptorship on NSCLC and SCLC

PROGRAMME

**ESMO
PRECEPTORSHIP**

**SINGAPORE
9-10 DECEMBER 2024**

Co-Chairs

Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

ESMO PRECEPTORSHIP PROGRAMME

NSCLC and SCLC

New standards of care and future perspectives

Singapore
9-10 December 2024

CO-CHAIRS: Tony S. K. Mok, Hong Kong SAR, China
Solange Peters, Switzerland

SPEAKERS: Thanyanan Baisamut, Thailand
Lizza Hendriks, The Netherlands
Molly S. C. Li, Hong Kong SAR, China
Calvin Ng, Hong Kong SAR, China
David Planchard, France
Sanjay Popat, United Kingdom
Jordi Remon Masip, France
Stephanie P. L. Saw, Singapore

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of SCLC

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AMGEN[®]



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Monday, 9 December 2024

09:00-09:10 10'	Welcome and introduction	Tony S. K. Mok, HK SAR, CN Solange Peters, CH
09:10-10:05 55'	SESSION 1 Screening	Chair: Solange Peters, CH
20'	Screening for smokers	Lizza Hendriks, NL
20'	Expanding screening to a non-smoking population	Molly S. C. Li, HK SAR, CN
15'	Q&A	All
10:05-10:35	Coffee break	
10:35-12:10 95'	SESSION 2 Advances in the treatment of early-stage lung cancer	Chair: Tony S. K. Mok, HK SAR, CN
20'	Innovative surgical approach to early-stage disease	Calvin Ng, HK SAR, CN
20'	Perioperative I/O	Solange Peters, CH
20'	Perioperative TKIs	Molly S. C. Li, HK SAR, CN
20'	The treatment paradigm for unresectable stage III NSCLC	Sanjay Popat, UK
15'	Q&A	All
12:10-13:10	Lunch	
13:10-14:05 55'	SESSION 3 Advanced-stage lung cancer	Chair: Tony S. K. Mok, HK SAR, CN
20'	State-of-the-art in immunotherapy for advanced-stage disease	Jordi Remon Masip, FR
20'	Addressing resistance with immunotherapy	Solange Peters, CH
15'	Q&A	All
14:05-15:25 80'	SESSION 4 Targeting the target	Chair: Solange Peters, CH
25'	Optimal approach for ADC in lung cancer	Tony S. K. Mok, HK SAR, CN
20'	What is new about EGFR mutations	Thanyanan Baisamut, TH
20'	Can we conquer KRAS mutations?	Tony S. K. Mok, HK SAR, CN
15'	Q&A	All
15:25-15:55	Coffee break	
15:55-16:55 60'	SESSION 5 Clinical cases on NSCLC and SCLC	Chair: Tony S. K. Mok, HK SAR, CN Solange Peters, CH
60'	Participants clinical case discussion (4x15') NSCLC x 2 cases SCLC x 2 cases	Faculty
19:00	Dinner	

Tuesday, 10 December 2024

09:00-10:15 75'	SESSION 6 SCLC	Chair: Tony S. K. Mok, HK SAR, CN
20'	Optimal management of limited-stage SCLC	David Planchard, FR
20'	Practical approach to genomic analysis of SCLC	Lizza Hendriks, NL
20'	Optimal management of ES-SCLC	Stephanie P. L. Saw, SG
15'	Q&A	All
10:15-10:45	Coffee break	
10:45-11:40 55'	SESSION 7 Novel approach to SCLC	Chair: Solange Peters, CH
20'	Bi-specific T-cell engager therapy	David Planchard, FR
20'	Novel ADC for SCLC	Sanjay Popat, UK
15'	Q&A	All
11:40-11:50 10'	Conclusion and farewell	Tony S. K. Mok, HK SAR, CN Solange Peters, CH
11:50-13:00	Lunch	

Note: Each 15-min slot for clinical case discussion includes 7' case presentation and 8' Q&A / interactive panel discussion